Apex Laboratory · Compound explained · Evidence checked September 8, 2026
PT-141 is another name for bremelanotide, a cyclic peptide that activates melanocortin receptors. A specific medicine containing it, Vyleesi, is approved for a defined low-desire disorder in premenopausal women. That approval does not make a research vial an approved medicine or establish a general sexual-performance benefit.
What the strongest trials found: improved reported desire and reduced distress related to low desire. The number of satisfying sexual events did not improve significantly. Those are distinct outcomes, and both belong in an explanation of the benefits.
Are PT-141 and bremelanotide the same thing?
They name the same active molecule. PT-141 is its development code; bremelanotide is its drug name. It is a seven-residue peptide with a constrained ring, an acetylated N terminus and a free-acid C terminus.
Free-acid ending
The parent structure is C₅₀H₆₈N₁₄O₁₀, about 1025.2 g/mol. The acetate formulation includes its salt components.
Melanotan II ending
Melanotan II has the corresponding amidated terminus. A shared melanocortin ancestry does not make the two compounds interchangeable.
The sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with an Asp-to-Lys side-chain lactam ring. The PubChem parent structure and the medicine’s description distinguish the molecule from its formulation. For the other compound’s evidence, see the Melanotan II research guide.
Same molecule does not mean the same product
Vyleesi has a specified formulation, manufacturing controls, delivery device and prescribing information. A laboratory material labeled PT-141 has its own identity and analytical record. It does not inherit Vyleesi’s finished-drug approval or clinical evidence. Research grade versus pharmaceutical grade.
How does PT-141 work?
Bremelanotide is a nonselective melanocortin receptor agonist. It engages more than one receptor subtype. The current prescribing information identifies MC1R and MC4R binding as most relevant at therapeutic exposure, while noting that the mechanism of improvement in HSDD remains unknown.
MC4R
Present in central nervous system circuits. Human and animal work investigates how this signaling contributes to sexual motivation and processing.
MC1R
Expressed on pigment-producing cells. Its activation helps explain why skin darkening appears in the medicine’s warnings.
These are roles, not equal potency values or an exclusive target map. Current Vyleesi prescribing information, section 12.1.
The broader melanocortin system also regulates appetite, energy balance and other functions. Its receptors share structural similarities without identical biological roles. Background reviews of POMC-derived hormones, receptor evolution, central circuits and MC4R physiology explain why “the libido receptor” is an oversimplification.
What did the human brain study add?
A randomized crossover study recruited 40 women with HSDD; 31 completed both bremelanotide and placebo visits. Brain imaging showed changes in responses to sexual stimuli, including increased activity in some regions and decreased activity in another. The result supports central processing as part of the explanation, without proving that every effect is mediated only by MC4R. Thurston and colleagues, 2022.
Separately, structural researchers resolved bremelanotide bound to MC4R with its signaling protein. Seeing one receptor complex does not establish absence of binding at other receptors. Primary structural study · Broader ligand review.
What benefits did the clinical trials show?
The two 24-week RECONNECT trials studied premenopausal women with hypoactive sexual desire disorder, or HSDD. This means low desire associated with distress, not simply a preference for more sexual activity. Primary phase 3 publication.
Integrated difference versus placebo in the Female Sexual Function Index desire domain. Higher means more desire; p < .001.
Integrated difference versus placebo in the low-desire distress item. Lower means less distress; p < .001.
The prespecified count outcome did not significantly improve. A later exploratory analysis of the proportion of encounters considered satisfying is a different endpoint.
The first two numbers are questionnaire score differences, not percentages of people helped. The trial population was predominantly White, and treatment discontinuation was higher with bremelanotide. Those limits matter when interpreting the average benefit.
What about longer-term results?
The 52-week extension reported sustained improvements among participants who continued. It had no placebo comparator during that phase and selected people who had completed the earlier study. Its results are therefore vulnerable to selection and dropout effects. Primary extension report.
Earlier evidence was smaller and used different conditions. A crossover study of 18 women reported some improvements in desire and arousal satisfaction, but no significant change in the measured vaginal vascular response. Its intranasal formulation and arousal-disorder population should not be merged with the later HSDD program. Diamond and colleagues, 2006.
Does PT-141 work for men, and is it better than Viagra?
Early controlled studies in men reported erectile responses measured with RigiScan. They included healthy volunteers and selected men with erectile dysfunction, using intranasal or subcutaneous study formulations. Those observations are real research findings, but they do not establish a broad male indication or superiority to sildenafil. Intranasal study · Subcutaneous study.
Sildenafil, the active ingredient in Viagra, is a PDE5 inhibitor. Bremelanotide uses melanocortin signaling. Different mechanisms do not demonstrate that one works better, or that combining them is appropriate for a particular person. The current Vyleesi label is not an approval for men or sexual-performance enhancement.
Two frequently repeated studies need a warning attached
The 2008 sildenafil-nonresponder study has a 2023 expression of concern. Separately, a 2008 trial in women is retracted by the journal. An expression of concern and a retraction are different editorial actions; neither should disappear when a website repeats a favorable headline.
This guide does not use either paper’s efficacy numbers to claim a benefit. Their publication status does not invalidate every other bremelanotide study.
How long does PT-141 take to work, and how long does it last?
The answer depends on whether “work” means a blood concentration, a reported experience or an established clinical effect. These should not be combined into one guaranteed clock.
- Plasma half-lifeThe Vyleesi label reports a mean terminal half-life of approximately 2.7 hours after its specified subcutaneous formulation. This is a pharmacokinetic measurement, not a duration of desire.
- Reported experienceIn the 31-completer brain study, participants were contacted 24 hours later and asked about increased desire during the preceding period. A positive response did not mean an uninterrupted effect lasting 24 hours.
- Duration of efficacyThe prescribing information says the duration of efficacy after a dose is unknown and the optimal timing window is not fully characterized. A research vial or nasal product cannot inherit a timing guarantee from that label.
Prescribing information, sections 2.1 and 12.3 · Actual 24-hour follow-up method.
If a prescribed treatment is not helping, taking more or adding another compound is not a conclusion that follows from these studies. A prescriber can assess the diagnosis, response, contraindications and formulation. This research guide provides no dose escalation, cycle or combination schedule.
What are the side effects, and who should avoid it?
Nausea was common
Reported across the pivotal trials. About 8% stopped treatment because of nausea. Flushing and headache were also common. These are trial rates, not a forecast for a different research product.
The cardiovascular warning matters
Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease. The label describes transient blood-pressure increases and heart-rate reductions. This is more consequential than describing the compound simply as a libido enhancer.
The label also warns about localized skin darkening, which may not fully resolve, and interactions caused by slowed stomach emptying. Oral naltrexone exposure can fall substantially. Pregnancy and other medical circumstances require clinician review; this paragraph is not the complete prescribing information. Full current safety and interaction information.
Approval also does not mean every evidence gap has closed. A breast-milk study, NCT06867835, lists ten actual participants and completed status, but no posted results in its January 2026 update. That registration alone cannot establish infant safety.
What exactly did FDA approve?
FDA approved Vyleesi under NDA 210557 on June 21, 2019. The indication concerns premenopausal women with acquired, generalized HSDD: distressing low desire that developed after a period without the problem and is not limited to one situation or partner. It excludes low desire attributable to another medical or psychiatric condition, relationship difficulties, or a drug’s effects. Original approval letter.
The current label retains that specific population. It is not an indication for postmenopausal women, men or general performance enhancement. The DailyMed package was updated November 13, 2025; its prescribing-information revision is March 2024. A later package date is not evidence of a newly expanded indication.
An Apex PT-141 research material is not Vyleesi. Reading a drug study can explain the molecule’s research history, but it does not establish equivalence of formulation, manufacturing or intended use.
Where did PT-141 come from?
Its lineage runs through melanocortin analogue research associated with Sawyer, Hruby, Hadley and colleagues at the University of Arizona. The 1982 cyclic α-MSH paper studied a different analogue in pigment-response models; its dramatic frog-skin potency result was not a PT-141 human effect. Foundational analogue paper.
The 1998 Melanotan I and II review and 2006 historical synthesis document the broader development story. The latter describes Palatin’s PT-141 as a new Melanotan II analogue entering clinical development. Historical plans should not be mistaken for current trial status.
Early PT-141 work in female rats found increased solicitation without changes in some other sexual behaviors. Those experiments and the subsequent mechanistic overview helped frame desire-related research; they did not measure human efficacy. Primary rat experiment · Preclinical overview.
A frequently cited male-rat brain-and-spinal-cord experiment instead tested Melanotan II. Its central mechanism findings should not be relabeled as a PT-141 experiment. Check the actual compound.
What should researchers check in a PT-141 material?
Start with the molecule, formulation and evidence for the actual sample. A 2026 analytical study characterized eight degradation products after deliberately stressing bremelanotide acetate. Its partly validated HPLC method and mass-spectrometry work show why a single purity number is incomplete. Computational predictions about those degradants were not observed patient toxicity. Primary degradation study.
- Identity: distinguish PT-141’s free-acid structure from Melanotan II, and identify any salt or formulation specification.
- Quantity and purity: distinguish labeled mass, measured content and chromatographic peak-area percentage. They are different measurements.
- Record scope: match the sample identifier, issue date and actual tests; a report does not automatically identify the shipping lot.
- Evidence supplied: scalar results and modeled displays are not original instrument records, and a COA does not demonstrate clinical benefit or pharmaceutical equivalence.
Use the COA reading guide and Lab Verified library for the applicable record. The PT-141 research-material page lists current configurations and availability; the specialty research overview connects related topics.
For laboratory research only. Not for human or veterinary use. No dose, injection, reconstitution or clinical-substitution instructions are provided here.
Frequently Asked Questions
Are PT-141 and bremelanotide the same molecule?
Yes. PT-141 is the development code for bremelanotide. That does not make a research material equivalent to Vyleesi, the approved finished medicine containing bremelanotide.
What benefits does PT-141 have?
The pivotal Vyleesi studies improved reported sexual desire and reduced related distress in premenopausal women with HSDD. They did not significantly improve the count of satisfying sexual events. Those findings do not establish the clinical performance of research material.
Is PT-141 effective for men?
Early controlled male studies reported erectile responses, but the current Vyleesi label does not include men. Research findings, an approved indication and an appropriate individual treatment are different questions.
Is PT-141 better than Viagra?
The studies reviewed here do not establish broad superiority over sildenafil. Bremelanotide acts through melanocortin signaling, whereas sildenafil is a PDE5 inhibitor. Different mechanisms do not prove that combining them is safe or effective for an individual.
How long does PT-141 last?
There is no guaranteed duration that applies to every PT-141 product. The Vyleesi label reports a mean terminal half-life of approximately 2.7 hours, but states that the duration of efficacy is unknown. A blood concentration is not the same as a duration of desire.
Who should not use Vyleesi?
The medicine is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. Its prescribing information contains additional warnings, interactions and population restrictions. Those need a clinician's review and cannot be replaced by a research-material guide.
Does PT-141 cause nausea or skin darkening?
Nausea was common in the pivotal bremelanotide trials. The Vyleesi label also warns about localized hyperpigmentation that may not fully resolve. This is not evidence that all formulations have the same frequency or severity of effects.
Is PT-141 the same as Melanotan II?
No. They are related melanocortin analogues with different terminal chemistry. Bremelanotide has a free-acid ending, whereas Melanotan II has the corresponding amidated ending. Their studies and product records should not be interchanged.
References
The source review checked the current prescribing information, original trial reports, relevant registry records and publication corrections on September 8, 2026. All linked PubMed identities were verified; available abstracts and selected full reports were read. The retracted paper and expression of concern are cited only for their publication status, not as evidence of efficacy.
- Sawyer TK et al. [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. Proceedings of the National Academy of Sciences of the United States of America. 1982. PMID 6281785.
- Hadley ME et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharmaceutical biotechnology. 1998. PMID 9760697.
- Hadley ME et al. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006. PMID 16412534.
- Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The journal of sexual medicine. 2006. PMID 16839319.
- Zhang H et al. Structural insights into ligand recognition and activation of the melanocortin-4 receptor. Cell research. 2021. PMID 34433901.
- Cone RD et al. Anatomy and regulation of the central melanocortin system. Nature neuroscience. 2005. PMID 15856065.
- Wessells H et al. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience. 2003. PMID 12710982.
- Hadley ME et al. The proopiomelanocortin system. Annals of the New York Academy of Sciences. 1999. PMID 10816638.
- Schiöth HB et al. Evolutionary conservation of the structural, pharmacological, and genomic characteristics of the melanocortin receptor subtypes. Peptides. 2005. PMID 15985310.
- Tao YX et al. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocrine reviews. 2010. PMID 20190196.
- Pfaus J et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. The journal of sexual medicine. 2007. PMID 17958619.
- Yuan XC et al. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. 2022. PMID 36291616.
- Pfaus JG et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America. 2004. PMID 15226502.
- Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology. 2019. PMID 31599840.
- Rosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research. 2004. PMID 14999221.
- Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International journal of impotence research. 2004. PMID 14963471.
- Simon JA et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and gynecology. 2019. PMID 31599847.
- Safarinejad MR et al. Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. The Journal of urology. 2023. PMID 36626345.
- Yuvaraaj VK et al. Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. Analytical methods : advancing methods and applications. 2026. PMID 42485063.
- Thurston L et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. The Journal of clinical investigation. 2022. PMID 36189794.
